PURPOSE: Increasing popularity and improved technical feasibility of partial nephrectomy (PN) has encouraged urologists to treat larger renal masses with nephron-sparing surgery. We used a national database to characterize practice patterns for the surgical management of patients with T2 renal tumors and examined the effect of PN on cancer-specific survival in such patients. METHODS: Between 2001 and 2011, 10,259 patients with primary tumor size >7 cm confined to the kidney (T2) were treated surgically for kidney cancer. PN trends were examined using annual percentage change (APC). Multivariate survival models were developed to identify independent determinants of PN use and cancer-specific survival (CSS) following surgical treatment of kidney cancer. RESULTS: Overall, 543 patients (5.29 %) were treated with PN versus 9716 (94.71 %) who underwent radical nephrectomy (RN). The use of PN increased progressively between 2001 and 2011 (APC +11.1 %, p < 0.05). Male gender, geographic location, year of diagnosis, and disease stage were independent determinants of increased PN use (all p values <0.05). Cancer-specific mortality was not inferior for patients treated with PN versus RN (HR 0.68, 95 % CI 0.50-0.94). Male gender, younger age, white race, tumor size >10 cm, localized disease, and papillary histology were all associated with improved CSS with PN (all p values <0.05). CONCLUSIONS: PN is increasingly utilized to treat T2 renal masses. Our analysis demonstrates that PN for T2 renal masses has no contraindicated effect on CSS.
PURPOSE: Increasing popularity and improved technical feasibility of partial nephrectomy (PN) has encouraged urologists to treat larger renal masses with nephron-sparing surgery. We used a national database to characterize practice patterns for the surgical management of patients with T2 renal tumors and examined the effect of PN on cancer-specific survival in such patients. METHODS: Between 2001 and 2011, 10,259 patients with primary tumor size >7 cm confined to the kidney (T2) were treated surgically for kidney cancer. PN trends were examined using annual percentage change (APC). Multivariate survival models were developed to identify independent determinants of PN use and cancer-specific survival (CSS) following surgical treatment of kidney cancer. RESULTS: Overall, 543 patients (5.29 %) were treated with PN versus 9716 (94.71 %) who underwent radical nephrectomy (RN). The use of PN increased progressively between 2001 and 2011 (APC +11.1 %, p < 0.05). Male gender, geographic location, year of diagnosis, and disease stage were independent determinants of increased PN use (all p values <0.05). Cancer-specific mortality was not inferior for patients treated with PN versus RN (HR 0.68, 95 % CI 0.50-0.94). Male gender, younger age, white race, tumor size >10 cm, localized disease, and papillary histology were all associated with improved CSS with PN (all p values <0.05). CONCLUSIONS: PN is increasingly utilized to treat T2 renal masses. Our analysis demonstrates that PN for T2 renal masses has no contraindicated effect on CSS.
Authors: Hendrik Van Poppel; Luigi Da Pozzo; Walter Albrecht; Vsevolod Matveev; Aldo Bono; Andrzej Borkowski; Jean-Marie Marechal; Laurence Klotz; Eila Skinner; Thomas Keane; Ilse Claessens; Richard Sylvester Journal: Eur Urol Date: 2006-11-15 Impact factor: 20.096
Authors: Christopher J Long; Daniel J Canter; Alexander Kutikov; Tianyu Li; Jay Simhan; Marc Smaldone; Ervin Teper; Rosalia Viterbo; Stephen A Boorjian; David Y T Chen; Richard E Greenberg; Robert G Uzzo Journal: BJU Int Date: 2012-01-05 Impact factor: 5.588
Authors: Stephen F Derose; Mark P Rutkowski; Peter W Crooks; Jiaxiao M Shi; Jean Q Wang; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Nathan W Levin; Steven J Jacobsen Journal: Am J Kidney Dis Date: 2013-03-15 Impact factor: 8.860
Authors: David C Miller; John M Hollingsworth; Khaled S Hafez; Stephanie Daignault; Brent K Hollenbeck Journal: J Urol Date: 2006-03 Impact factor: 7.450
Authors: Tullika Garg; Laura C Pinheiro; Coral L Atoria; S Machele Donat; Joel S Weissman; Harry W Herr; Elena B Elkin Journal: J Urol Date: 2014-05-14 Impact factor: 7.450
Authors: Ryan P Kopp; Reza Mehrazin; Kerrin L Palazzi; Michael A Liss; Ramzi Jabaji; Hossein S Mirheydar; Hak J Lee; Nishant Patel; Fuad Elkhoury; Anthony L Patterson; Ithaar H Derweesh Journal: BJU Int Date: 2014-10-03 Impact factor: 5.588
Authors: Francesco Greco; Riccardo Autorino; Vincenzo Altieri; Steven Campbell; Vincenzo Ficarra; Inderbir Gill; Alexander Kutikov; Alex Mottrie; Vincenzo Mirone; Hendrik van Poppel Journal: Eur Urol Date: 2018-10-13 Impact factor: 24.267